Treatment approaches for advanced cutaneous melanoma

Journal of Drugs in Dermatology

Volumn 7, Issue 2, 2008, Pages 175-179

  Stein, Jennifer A ^a   Brownell, Isaac ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CLINICAL TRIAL; DRUG THERAPY; HUMAN; IMMUNOTHERAPY; MELANOMA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; SKIN TUMOR;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 44449116729     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. NCCN Clinical Practice Guidelines in Oncology. Melanoma v.2.2007. Available at: http://www.nccn.org/professionals/ physician-gls/PDF/melanoma.pdf. Accessed December 2007.
2. Balch CM, Buzaid AC, Soong S-J, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635-3648. (Pubitemid 32786276)
3. Balch CM, Buzaid AC, Soong, S-J, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003;21:43-52. (Pubitemid 37127473)
4. Morton, DL, Thompson, JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317. (Pubitemid 44465459)
5. Atkins MB, Lee S, Flaherty LE, et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon a-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:708.
6. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol. 2001;2:193-202.
7. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dcarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166. (Pubitemid 30036349)
8. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144-151. (Pubitemid 30238234)
9. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751. (Pubitemid 29415231)
10. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117-127.
11. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95:581-586. (Pubitemid 44325897)
12. Hyunh NT, Veness MJ. Radiotherapy for Lentigo Maligna. Arch Derm. 2002;138:981-982.
13. Bastiaannet E, Beukema J, Hoekstra H. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18-26. (Pubitemid 40246987)
14. Ralph SJ. An update on malignant melanoma vaccine research. Am J Clin Dermatol. 2007;8:123-141.
15. He YF, Wang XH, Zhang GM, et al. Sustained low-level expression of interferon gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother. 2005;54:891-897.
16. Mann A, Breuhahn K, Schirmacher P, et al. Up- and down-regulation of granulocyte/macrophage-colony stimulating factor activity in murine skin increase susceptibility to skin carcinogenesis by independent mechanisms. Cancer Res. 2001;61(5):2311-2319. (Pubitemid 32692065)
17. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res. 2006;12:2337s-2341s.
18. Slingluff CL, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007;13:6386-6395. (Pubitemid 350075028)
19. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA. 2004;101(suppl 2):14567-14571.
20. Yang Y, Li Q, Ertl HCJ, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;67:2004-2015.
21. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA. 1995;92:1401-1405.
22. Cassaday RD, Sondel PM, King DM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 2007;13:540-549. (Pubitemid 46225360)
23. Zhang S, Wang Q, Miao B. Dendritic cell-based vaccine in the treatment of patients with advanced melanoma. Cancer Biother Radiopharm. 2007;22:501-507. (Pubitemid 47403470)
24. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res. 2001;7:1882-1887. (Pubitemid 32994821)
25. Bystryn JC, Reynolds SR. Melanoma vaccines: what we know so far. Oncology (Williston Park). 2005;1:97-108. (Pubitemid 350056480)
26. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res. 2006;12:2353s-2358s.
27. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
28. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin- 2 therapy in patients with metastatic melanoma: longterm survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14.
29. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907-913.
30. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106:1431-1432.
31. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543. (Pubitemid 23111402)
32. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow- derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965. (Pubitemid 24196166)
33. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte- macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 1998;95:13141-13146.
34. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 2007;25:613-631. (Pubitemid 350135746)
35. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101(suppl 2):14639-14645. (Pubitemid 39346736)
36. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130. (Pubitemid 39628146)